Su­cam­po shut­ters de­vel­op­ment ef­fort af­ter lead drug flops in back-to-back stud­ies

Back in April, when Su­cam­po’s lead ex­per­i­men­tal drug co­bipro­s­tone flunked its first mid-stage study, the Rockville, MD-based biotech stub­born­ly in­sist­ed that an on­go­ing study for an­oth­er in­di­ca­tion of­fered a whole new path­way for­ward. To­day, that road came to an end, and the drug did too.

A fu­til­i­ty analy­sis of the drug in a Phase IIa study of an oral spray for­mu­la­tion of co­bipro­s­tone for the pre­ven­tion of oral mu­cosi­tis in pa­tients that are un­der­go­ing ra­dio chemother­a­py for head and neck can­cer con­clud­ed that the study was an­oth­er flop. And Su­cam­po says it’s mov­ing on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.